BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 26695071)

  • 1. Long-lasting activity of trabectedin in refractory uterine leiomyosarcoma: a case report.
    Bongiovanni A; Riva N; Ricci M; Mercatali L; Liverani C; La Manna F; De Vita A; Cavaliere D; Pieri F; Oboldi D; Verdecchia GM; Amadori D; Ibrahim T
    BMC Cancer; 2015 Dec; 15():998. PubMed ID: 26695071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trabectedin clinical cases: use according to indication in diverse clinical scenarios.
    Grignani G; Martín-Broto J; Schuler M; Reichardt P
    Future Oncol; 2015; 11(11 Suppl):15-24. PubMed ID: 26043311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An increasing role for trabectedin in gynecological cancers: efficacy in uterine sarcomas.
    Ray-Coquard I
    Int J Gynecol Cancer; 2011 May; 21 Suppl 1():S3-5. PubMed ID: 21540667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers.
    Sanfilippo R; Grosso F; Jones RL; Banerjee S; Pilotti S; D'Incalci M; Dei Tos AP; Raspagliesi F; Judson I; Casali PG
    Gynecol Oncol; 2011 Dec; 123(3):553-6. PubMed ID: 21917307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stable disease in a patient with metastatic leiomyosarcoma treated with trabectedin.
    Tavella K; Villanucci A; Vannini L; Lavacchi D; Montelatici S; Amunni G; Mazzei T
    Anticancer Drugs; 2017 Apr; 28(4):465-468. PubMed ID: 28181940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged disease stability with trabectedin in a heavily pretreated elderly patient with metastatic leiomyosarcoma of the thigh and renal failure: a case report and review of the literature.
    Galizia D; Palesandro E; Nuzzo AM; Pignochino Y; Aliberti S; Aglietta M; Grignani G
    Oncol Res; 2013; 20(10):483-90. PubMed ID: 24308159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma.
    Tewari D; Saffari B; Cowan C; Wallick AC; Koontz MZ; Monk BJ
    Gynecol Oncol; 2006 Sep; 102(3):421-4. PubMed ID: 16797679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
    De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
    Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.
    Hensley ML; Patel SR; von Mehren M; Ganjoo K; Jones RL; Staddon A; Rushing D; Milhem M; Monk B; Wang G; McCarthy S; Knoblauch RE; Parekh TV; Maki RG; Demetri GD
    Gynecol Oncol; 2017 Sep; 146(3):531-537. PubMed ID: 28651804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term response to first-line trabectedin in an elderly female patient with a metastatic leiomyosarcoma unfit for anthracycline.
    Maruzzo M; Brunello A; Diminutto A; Rastrelli M; Basso U
    Anticancer Drugs; 2016 Mar; 27(3):264-7. PubMed ID: 26629769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trabectedin in advanced soft tissue sarcoma: case series.
    Demirci U; Buyukberber S; Yetisyigit T; Dizdar O; Benekli M; Alkis N; Coskun U;
    J BUON; 2012; 17(3):591-2. PubMed ID: 23033305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The intriguing patterns of tumor response to trabectedin.
    Sanfilippo R; Casali PG
    Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):21-4. PubMed ID: 23638727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged disease stability with trabectedin in two monorenal patients with retroperitoneal sarcoma.
    Bruder F; Massa D; Barca M; Contu V; Airoldi M; Crova A
    Tumori; 2014; 100(3):e63-6. PubMed ID: 25076252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study.
    Monk BJ; Blessing JA; Street DG; Muller CY; Burke JJ; Hensley ML
    Gynecol Oncol; 2012 Jan; 124(1):48-52. PubMed ID: 21996263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.
    Pautier P; Floquet A; Chevreau C; Penel N; Guillemet C; Delcambre C; Cupissol D; Selle F; Isambert N; Piperno-Neumann S; Thyss A; Bertucci F; Bompas E; Alexandre J; Collard O; Lavau-Denes S; Soulié P; Toulmonde M; Le Cesne A; Lacas B; Duffaud F;
    Lancet Oncol; 2015 Apr; 16(4):457-64. PubMed ID: 25795402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Danish experience with trabectedin treatment for metastatic sarcoma: Importance of hyponatremia.
    Schack LH; Mouritsen LS; Elowsson C; Krarup-Hansen A; Safwat A
    Acta Oncol; 2015 Jan; 54(1):34-40. PubMed ID: 25263179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients.
    Hollebecque A; Adenis A; Taieb S; Lebedinsky C; Penel N
    Invest New Drugs; 2010 Aug; 28(4):529-30. PubMed ID: 19430728
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
    Demetri GD; Chawla SP; von Mehren M; Ritch P; Baker LH; Blay JY; Hande KR; Keohan ML; Samuels BL; Schuetze S; Lebedinsky C; Elsayed YA; Izquierdo MA; Gómez J; Park YC; Le Cesne A
    J Clin Oncol; 2009 Sep; 27(25):4188-96. PubMed ID: 19652065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG).
    Kasper B; Reichardt P; Pink D; Sommer M; Mathew M; Rauch G; Hohenberger P
    Mar Drugs; 2015 Jan; 13(1):379-88. PubMed ID: 25591040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trabectedin in soft tissue sarcomas.
    Petek BJ; Loggers ET; Pollack SM; Jones RL
    Mar Drugs; 2015 Feb; 13(2):974-83. PubMed ID: 25686274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.